We are honored to participate in the highly anticipated ESHRE 2024 Conference, a global stage where the future of reproductive medicine takes shape. This premier event brings together renowned scientists, clinicians, and innovators to share groundbreaking discoveries, transformative treatments, and state-of-the-art technologies.
At this year’s conference, Prolistem is taking center stage with the presentation of compelling clinical data that highlights its revolutionary potential. Specifically, a randomized study on non-obstructive azoospermia (NOA) demonstrated Prolistem’s significant impact on enhancing MicroTESE success rates. The results revealed a 60% success rate in sperm retrieval among patients treated with Prolistem compared to just 20% in the control group, underscoring its transformative role in addressing male infertility.
Prolistem is built on years of rigorous research and is underpinned by an innovative mechanism of action: the temporary reduction of testosterone in Leydig cells. This strategic modulation appears to activate non-classical signaling pathways, which support spermatogonial stem cell proliferation, without disrupting overall androgen function. While the precise mechanisms remain under study, ongoing research—led by experts like Dr. Marvin Meistrich and validated through clinical outcomes—consistently affirms its efficacy.
Key questions have emerged about Prolistem’s unique therapeutic strategy, such as its ability to balance hormonal cascades during testosterone suppression and restoration phases and its role in survival-mode activation of non-classical pathways. By leveraging a minimal yet targeted reduction of testosterone (15-20%), Prolistem stimulates alternative signaling pathways while maintaining systemic balance. This nuanced approach has been recognized for its safety and effectiveness, even in complex cases like Sertoli cell-only syndrome or maturation arrest.
Prolistem’s journey reflects the challenges and triumphs of a small, dedicated team committed to revolutionizing male infertility care. While resource constraints have delayed its incorporation into mainstream guidelines, Prolistem is gaining prominence globally, particularly in the Middle East, where it is registered and endorsed by leading experts and associations, including the Turkish Andrology Association. Plans for a multicenter clinical trial in Turkey aim to further solidify its role as a groundbreaking therapeutic option.
We are immensely proud of our progress and look forward to fostering collaborations, gathering insights, and staying at the forefront of reproductive medicine to bring hope to patients worldwide. Our commitment remains steadfast: to empower individuals and couples struggling with infertility by offering science-backed, accessible solutions that transform lives.